Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 107.35 Million USD | 69.19% |
| 2022 | 63.45 Million USD | 3.8% |
| 2021 | 61.12 Million USD | 3.9% |
| 2020 | 58.83 Million USD | 7.45% |
| 2019 | 54.75 Million USD | 6.55% |
| 2018 | 51.38 Million USD | 14.18% |
| 2017 | 45 Million USD | 0.81% |
| 2016 | 44.64 Million USD | 1.08% |
| 2015 | 44.16 Million USD | -26.26% |
| 2014 | 59.89 Million USD | 144.01% |
| 2013 | 24.54 Million USD | 83.49% |
| 2012 | 13.37 Million USD | 37.62% |
| 2011 | 9.72 Million USD | -13.23% |
| 2010 | 11.2 Million USD | -48.95% |
| 2009 | 21.94 Million USD | -83.88% |
| 2008 | 136.15 Million USD | 88.43% |
| 2007 | 72.25 Million USD | 5.25% |
| 2006 | 68.65 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 111.58 Million USD | -0.22% |
| 2024 Q1 | 111.83 Million USD | 4.17% |
| 2023 FY | 107.35 Million USD | 69.19% |
| 2023 Q3 | 105.35 Million USD | -3.07% |
| 2023 Q2 | 108.69 Million USD | 61.85% |
| 2023 Q4 | 107.35 Million USD | 1.9% |
| 2023 Q1 | 67.15 Million USD | 5.84% |
| 2022 Q2 | 59.9 Million USD | 2.35% |
| 2022 Q4 | 63.45 Million USD | 3.16% |
| 2022 Q1 | 58.53 Million USD | -4.24% |
| 2022 FY | 63.45 Million USD | 3.8% |
| 2022 Q3 | 61.5 Million USD | 2.67% |
| 2021 Q4 | 61.12 Million USD | 4.37% |
| 2021 FY | 61.12 Million USD | 3.9% |
| 2021 Q1 | 57.54 Million USD | -2.19% |
| 2021 Q2 | 56.21 Million USD | -2.32% |
| 2021 Q3 | 58.56 Million USD | 4.18% |
| 2020 Q3 | 56.71 Million USD | 0.16% |
| 2020 Q2 | 56.62 Million USD | 4.08% |
| 2020 Q1 | 54.4 Million USD | -0.64% |
| 2020 Q4 | 58.83 Million USD | 3.74% |
| 2020 FY | 58.83 Million USD | 7.45% |
| 2019 Q4 | 54.75 Million USD | 2.91% |
| 2019 Q2 | 53.92 Million USD | 4.37% |
| 2019 Q3 | 53.2 Million USD | -1.33% |
| 2019 FY | 54.75 Million USD | 6.55% |
| 2019 Q1 | 51.66 Million USD | 0.54% |
| 2018 Q3 | 48.23 Million USD | -2.16% |
| 2018 Q1 | 47.56 Million USD | 5.69% |
| 2018 FY | 51.38 Million USD | 14.18% |
| 2018 Q4 | 51.38 Million USD | 6.54% |
| 2018 Q2 | 49.29 Million USD | 3.64% |
| 2017 Q3 | 43.99 Million USD | -0.4% |
| 2017 Q2 | 44.17 Million USD | 3.87% |
| 2017 Q1 | 42.52 Million USD | -4.75% |
| 2017 FY | 45 Million USD | 0.81% |
| 2017 Q4 | 45 Million USD | 2.3% |
| 2016 Q2 | 46.96 Million USD | 4.11% |
| 2016 FY | 44.64 Million USD | 1.08% |
| 2016 Q3 | 44.94 Million USD | -4.29% |
| 2016 Q4 | 44.64 Million USD | -0.68% |
| 2016 Q1 | 45.1 Million USD | 2.14% |
| 2015 Q2 | 53.99 Million USD | -4.03% |
| 2015 FY | 44.16 Million USD | -26.26% |
| 2015 Q4 | 44.16 Million USD | -3.26% |
| 2015 Q3 | 45.65 Million USD | -15.46% |
| 2015 Q1 | 56.26 Million USD | -6.06% |
| 2014 Q2 | 34.99 Million USD | -4.81% |
| 2014 Q1 | 36.76 Million USD | 49.79% |
| 2014 FY | 59.89 Million USD | 144.01% |
| 2014 Q4 | 59.89 Million USD | -29.59% |
| 2014 Q3 | 85.06 Million USD | 143.06% |
| 2013 Q1 | 17.45 Million USD | 30.51% |
| 2013 Q4 | 24.54 Million USD | 15.03% |
| 2013 Q2 | 27.88 Million USD | 59.72% |
| 2013 FY | 24.54 Million USD | 83.49% |
| 2013 Q3 | 21.33 Million USD | -23.48% |
| 2012 Q2 | 6.88 Million USD | -11.07% |
| 2012 Q4 | 13.37 Million USD | 66.61% |
| 2012 Q1 | 7.74 Million USD | -20.36% |
| 2012 Q3 | 8.02 Million USD | 16.63% |
| 2012 FY | 13.37 Million USD | 37.62% |
| 2011 Q3 | 9.7 Million USD | 5.26% |
| 2011 FY | 9.72 Million USD | -13.23% |
| 2011 Q1 | 10.16 Million USD | -9.23% |
| 2011 Q4 | 9.72 Million USD | 0.11% |
| 2011 Q2 | 9.22 Million USD | -9.28% |
| 2010 Q4 | 11.2 Million USD | 110.25% |
| 2010 Q2 | 5.23 Million USD | -97.14% |
| 2010 Q3 | 5.32 Million USD | 1.87% |
| 2010 Q1 | 182.74 Million USD | 732.82% |
| 2010 FY | 11.2 Million USD | -48.95% |
| 2009 Q3 | 152.06 Million USD | 0.0% |
| 2009 FY | 21.94 Million USD | -83.88% |
| 2009 Q4 | 21.94 Million USD | -85.57% |
| 2008 Q4 | 136.15 Million USD | 0.0% |
| 2008 FY | 136.15 Million USD | 88.43% |
| 2008 Q2 | 123.77 Million USD | 5.01% |
| 2008 Q1 | 117.86 Million USD | 0.0% |
| 2007 FY | 72.25 Million USD | 5.25% |
| 2006 FY | 68.65 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 88.674% |
| Embecta Corp. | 2.03 Billion USD | 94.727% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 77.24% |
| Dynavax Technologies Corporation | 375.02 Million USD | 71.374% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 83.754% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 84.756% |
| PainReform Ltd. | 2.69 Million USD | -3889.372% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 34.502% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -1648.55% |
| SCYNEXIS, Inc. | 55.45 Million USD | -93.605% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1067.321% |
| Cosmos Health Inc. | 30.25 Million USD | -254.86% |
| Journey Medical Corporation | 56.49 Million USD | -90.01% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -1648.55% |
| Safety Shot Inc | 3.89 Million USD | -2658.294% |
| Alpha Teknova, Inc. | 38.55 Million USD | -178.473% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 21.566% |
| Bright Green Corporation | 6.43 Million USD | -1567.479% |
| Procaps Group, S.A. | 462.06 Million USD | 76.766% |
| Theratechnologies Inc. | 98.63 Million USD | -8.835% |
| Harrow Health, Inc. | 241.75 Million USD | 55.594% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1126.062% |
| Biofrontera Inc. | 23.13 Million USD | -363.953% |
| DURECT Corporation | 30.4 Million USD | -253.068% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 77.977% |
| Cronos Group Inc. | 43.73 Million USD | -145.459% |
| OptiNose, Inc. | 194.33 Million USD | 44.758% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 86.866% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -121.6% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -411.743% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 40.807% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -2745.975% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -104.421% |
| Radius Health, Inc. | 804.29 Million USD | 86.652% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -680.511% |
| ProPhase Labs, Inc. | 42.54 Million USD | -152.336% |
| Phibro Animal Health Corporation | 725.54 Million USD | 85.204% |
| Procaps Group S.A. | 462.06 Million USD | 76.766% |
| Alvotech | 1.88 Billion USD | 94.298% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -665.611% |
| Viatris Inc. | 27.21 Billion USD | 99.606% |
| Rockwell Medical, Inc. | 30.88 Million USD | -247.626% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -18.782% |
| SIGA Technologies, Inc. | 57.97 Million USD | -85.166% |
| Tilray Brands, Inc. | 892.11 Million USD | 87.966% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 51.158% |
| Shineco, Inc. | 47.6 Million USD | -125.526% |
| PetIQ, Inc. | 645.22 Million USD | 83.362% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -48805.755% |
| Incannex Healthcare Limited | 5.83 Million USD | -1741.407% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 89.469% |
| Silver Spike Investment Corp. | 3 Million USD | -3466.778% |
| Assertio Holdings, Inc. | 148.41 Million USD | 27.667% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -5562.235% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -403.636% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -1427.953% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1164.397% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 38.084% |
| Hempacco Co., Inc. | 18.82 Million USD | -470.352% |
| Talphera, Inc. | 6.29 Million USD | -1606.741% |
| Alvotech | 1.88 Billion USD | 94.298% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 37.802% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 87.147% |
| Currenc Group, Inc. | 177.67 Million USD | 39.579% |
| Kamada Ltd. | 109.96 Million USD | 2.377% |
| Indivior PLC | 1.95 Billion USD | 94.498% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1012.698% |
| Flora Growth Corp. | 17.22 Million USD | -523.354% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1164.397% |
| Evolus, Inc. | 209.68 Million USD | 48.803% |
| HUTCHMED (China) Limited | 536.38 Million USD | 79.986% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 87.71% |
| Akanda Corp. | 12.66 Million USD | -747.383% |